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The Francis Crick Institute, London, United KingdomThe gastrointestinal (GI) tract is essential for the absorp-
tion of nutrients, induction of mucosal and systemic
immune responses, and maintenance of a healthy gut
microbiota. Key aspects of gastrointestinal physiology are
controlled by the enteric nervous system (ENS), which is
composed of neurons and glial cells. The ENS is exposed to
and interacts with the outer (microbiota, metabolites, and
nutrients) and inner (immune cells and stromal cells)
microenvironment of the gut. Although the cellular blue-
print of the ENS is mostly in place by birth, the functional
maturation of intestinal neural networks is completed
within the microenvironment of the postnatal gut, under
the inﬂuence of gut microbiota and the mucosal immune
system. Recent studies have shown the importance of
molecular interactions among microbiota, enteric neurons,
and immune cells for GI homeostasis. In addition to its role
in GI physiology, the ENS has been associated with the
pathogenesis of neurodegenerative disorders, such as
Parkinson’s disease, raising the possibility that micro-
biota–ENS interactions could offer a viable strategy for
inﬂuencing the course of brain diseases. Here, we discuss
recent advances on the role of microbiota and the immune
system on the development and homeostasis of the ENS, a
key relay station along the gut–brain axis.Keywords: Enteric Nervous System (ENS); Microbiota; Neuro-
immune Interaction; Parkinson’s Disease; Microbiota–
Gut–Brain Axis.
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energy balance, and protection from pathogenic microor-
ganisms. Most aspects of GI physiology are under neural
control, which is exerted via extrinsic nerves (which include
both primary afferent and autonomic ﬁbers that ultimately
connect the gut tissues with the central nervous system
[CNS]) and a vast network of intrinsic enteric neurons
(1–5  108) and glial cells that are organized into the
myenteric and submucosal plexi of the enteric nervous
system (ENS).1 On the basis of their neurochemical prop-
erties, enteric neurons are subdivided into multiple sub-
types that share molecular, morphologic, and physiological
characteristics.2,3 Unlike enteric neurons whose cell bodies
are restricted to the myenteric and submucosal ganglia,
enteric glial cells (EGCs), and neuronal ﬁbers are distributed
throughout the gut wall, including the lamina propria of the
mucosa.4,5 Among other functions, the ENS regulates GIperistalsis, epithelial secretion, intestinal blood ﬂow, and
transmucosal movement of liquids largely independently of
central nervous system input.1
In addition to itsmotor and secretory functions, theGI tract
is the largest sensory organ of the body, which incessantly
monitors the dynamic microenvironment of the gut wall and
its lumen.6 Several cellular systems contribute to the sensory
function of the gut, including the enteroendocrine cells of the
intestinal epithelium, the mucosal immune system, and the
ENS.1 The integrated responses of these cellular networks
enable the gut to build highly selective anatomic and func-
tional barriers that allow absorption of useful nutrients and
exclusion of harmful chemicals and micro-organisms. Infor-
mation relating to the chemical composition and caloric value
of ingested food, the dynamic equilibrium of the microbial
ecosystem of the gut (microbiota), and the physiological state
of the gut wall reaches the brain via the neurohumoral path-
ways of the microbiota–gut–brain (MGB) axis and allows the
CNS to generate appropriate homeostatic and behavioral
responses.6–8
Emerging evidence suggests that gut microﬂora can
have dramatic effects on the development and function of the
nervous system, both at the local as well as at the systemic
level. Although disruption of the physiological microbiota
composition (dysbiosis) is known to inﬂuence cognitive ac-
tivity and behavior, such as stress response, anxiety,
and memory,7,9 the mechanistic understanding of microbe–
neural interactions remains obscure. Because the ENS con-
stitutes a key relay station along the MGB axis, understanding
the mechanisms of ENS–microbe communication is essential
for deciphering how the gut microenvironment inﬂuences
physiology at the local and organismal level. Here, we provide
a brief overview of the impact of microbiota and the mucosal
immune system on ENS development and homeostasis.
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ENS Development
The ENS is derived from neuroectodermal progenitors
that originate mainly from the vagal neural crest, invade the
foregut during embryogenesis, and migrate rostrocaudaly to
colonize the entire GI tract. In mammals, enteric neuro-
genesis and gliogenesis occur mostly during embryonic and
fetal stages but a considerable fraction of enteric neurons
and glia are born within the postnatal gut.10 Furthermore,
functional maturation of intestinal neural circuits also
occurs within the early postnatal period.11 To date, the
development of the ENS has been examined primarily from
the point of view of genetic and molecular mechanisms that
operate within the neuroectodermal lineages of the gut.
These studies have identiﬁed several transcription factors,
such as SOX10 (an SRY-related HMG-box transcription fac-
tor), FOXD3 (a member of the forkhead protein family) and
HAND2,12–15 which control the survival and lineage choices
of ENS progenitors. In addition, ENS lineages express
several types of cell surface receptors, such as the receptor
tyrosine kinase RET and the G-protein–coupled endothelin
receptor B (EDNRB), which control multiple aspects of ENS
development and neural circuit assembly. RET and EDNRB
are activated by members of the GDNF family of ligands and
endothelin-3, respectively, which are produced by the in-
testinal mesenchyme, highlighting the key role of the
cellular microenvironment on the development of ENS lin-
eages.16 For a comprehensive recent review of the cellular
and molecular mechanisms underlying ENS development,
please refer to Lake et al.16
The Role of Gut Microbial Factors on
the Development and Homeostasis of
the ENS
Immediately after birth the GI tract is colonized by
complex microbial communities (>100 trillion microbes
belonging to w1000 species), which inﬂuence multiple
aspects of host physiology, including metabolism, immune
responses, behavior, and circadian rhythm.7,17–19 The role of
microbiota on ENS organization is highlighted by the
reduced number of enteric neurons and the associated
deﬁcits in gut motility observed in germ-free (GF) mice.20–22
In addition, GF mice show attenuated excitability of intrinsic
primary afferent neurons23 that are part of the hard-wired
gut-brain neural pathways.24 Furthermore, the develop-
ment and continuous homeostatic inﬂux of EGCs into the
intestinal mucosa is defective in GF mice.25 These observa-
tions argue that microbiota is essential for the assembly of
intestinal neural circuits and for signaling along the gut–
brain axis. Interestingly, reconstitution of GF mice with
conventional microbiota normalized the density of EGC
network and gut physiology,25,26 raising interesting ques-
tions relating to the cellular plasticity of the ENS and the
mechanisms by which microbiota inﬂuence its homeostasis.
A recent report showed that the reduction of myenteric
neurons in GF mice is present by postnatal day 327 when the
number and diversity of gut microbiota has not beenestablished,28 raising the possibility that, in addition to
factors associated with changes in early postnatal gut
physiology or feeding, maternal microbial factors may play a
role in ENS development during pregnancy via uteropla-
cental circulation. Consistent with this idea, microbial
colonization of the gut may occur before birth.29,30
Furthermore, recent evidence indicates that maternal
microbe-derived factors and the maternal immune system
contribute to the offspring’s immune and neuronal homeo-
stasis.31–34 Taken together, these observations suggest that
dynamic host–microbe interactions during critical develop-
mental periods could increase the risk of neuro-
developmental disorders and have long-term consequences
on neuronal function. Here, we summarize the impact of gut
microbial factors on ENS development and homeostasis.
Toll-Like–Receptor Ligands
Gut microbe-derived signals are recognized partly by
pattern recognition receptors, such as Toll-like receptors
(TLRs). TLR4-/- mice are characterized by abnormal intes-
tinal motility and a reduced number of nitrergic (neuronal
nitric oxide synthase [nNOS]þ) inhibitory neurons, a
phenotype similar to that observed in GF and antibiotic-
treated animals.22 This phenotype also was reproduced in
mice with ENS-speciﬁc deletion of MyD88, an adaptor
molecule essential for TLR-mediated signal transduction,
suggesting key roles of the TLR4 pathway on the develop-
ment and functional organization of intestinal neural
networks.22 A separate study showed that deletion of TLR2,
which is expressed by enteric neurons, EGCs, and smooth
muscle cells of the gut wall, also resulted in reduction of
nNOSþ neurons and acetylcholine-esterase–stained ﬁbers in
the myenteric ganglia.35 The altered neurochemical proﬁles
of enteric neurons in the gut of TLR2-deﬁcient mice was
accompanied by gut dysmotility and attenuated chloride
production by intestinal explants. Interestingly, expression
of glial markers, such as glial ﬁbrillary acidic protein (GFAP)
and S100b, also decreased in the myenteric plexus of
mutant mice. Considering that probiotic and pathogenic
bacteria up-regulate TLR2 expression on human EGCs,36
these studies suggest that the microbiota–TLR2 pathway
promotes functional maturation of EGCs. Interestingly,
expression of GDNF is reduced signiﬁcantly in TLR2-
deﬁcient and microbiota-depleted mice, while administra-
tion of GDNF rescued the ENS deﬁcits of these animals,
suggesting that the effects of TLR/microbiota pathways on
ENS development and homeostasis are mediated via
mesenchyme-derived neurotrophic factors. Outside the gut,
TLR4 regulates the expression of Sox10 and Foxd3, raising
the possibility that these transcriptional regulators also are
targets of TLR4 in the ENS.37,38 Nevertheless, the molecular
mechanisms by which TLR ligands control enteric neuro-
genesis during neonatal stages require further investigation.
Short-Chain Fatty Acids
Gut microbes metabolize dietary ﬁber and resistant
starch to produce a wide variety of metabolites, including
short-chain fatty acids (SCFAs), which are used as
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physiology.39–42 Recent studies have uncovered a role of
SCFAs in the production of serotonin (5-hydroxytryptamine
[5-HT]) by enterochromafﬁn cells (ECs) of the intestinal
epithelium.43,44 ECs are the largest source of serotonin in
the body, which, among other functions, regulate GI motility
and platelet function.45,46 Spore-forming bacteria from
healthy human beings and mouse microbiota increase
colonic and serum 5-HT levels in GF mice (by increasing
expression of the colonic biosynthetic enzyme tryptophan
hydroxylase 1-Tph143) and ameliorate GF-associated gut
dysmotility. These bacteria produce SCFAs,39,47 which are
capable of increasing 5-HT production by cultured chro-
mafﬁn cells43 and up-regulating Tph1 expression in a
human-derived EC cell line.44 In addition, the extracellular
availability of 5-HT within the gut is regulated by the
serotonin-selective reuptake transporter (SERT) which is
expressed by intestinal epithelial cells.48 Expression of SERT
is lower in neonatal gut in comparison with adult tissues,
resulting in higher availability of 5-HT, which during these
early stages is essential for the maturation of intestinal
motor reﬂexes.48,49 SERT expression by intestinal epithelial
cells also is regulated by microbiota-derived factors such as
TLR ligands because treatment of an epithelial cell line
(Caco-2) with lipopolysaccharide diminishes the expression
and activity of SERT.50 These observations suggest that
different kinds of microbial factors (eg, SCFAs and lipo-
polysaccharide) contribute to functional maturation of ENS
by regulating the production and availability of 5-HT in a
coordinated way.
SCFAs also can inﬂuence the neurochemical phenotype
of the ENS in adult rat.51 Resistant starch diet (RSD), which
enhances luminal SCFA concentration,52 speciﬁcally
increased the proportion of excitatory cholinergic neurons
in the colon, but had no effect on nNOSþ neurons, resulting
in decreased colonic transit time. Intrarectal administration
of butyrate, but not acetate or propionate, mimicked the
effect of RSD. Of note, the butyrate-induced increase in
excitatory choline acetyltransferase (ChAT)þ neurons
depended on the butyrate transporter monocarboxylate
transporter (MCT)2, which is expressed by enteric neu-
rons,51 but the factors regulating neuronal MCT2 expression
remain unknown. A recent study has shown that the EGC
cell line, JUG-2, also expresses MCT1 and MCT2,53 although
the physiological role of these enzymes on glial homeostasis
in vivo has not been determined.
SCFAs also activate G-protein–coupled receptors, such as
GPR41 and GPR43.54,55 Analysis of transgenic reporter mice
has shown that GPR41 is expressed by ECs and enteric
neurons,55 although the role of neuronal GPR41 on ENS
function has not been characterized. GPR43 is expressed by
intestinal immune cells and sporadically by ECs.55 Activa-
tion of GPR43 on enteroendocrine cells by SCFAs promotes
secretion of the incretin hormone glucagon-like peptide-1
(GLP-1),56 which also controls gastric emptying and
gastrointestinal transit.57 Moreover, RSD is known to in-
crease GLP-1 expression by cecal and colonic epithelial cells
in vivo,58 suggesting that gut microbiota may increase GLP-1
levels through the SCFAs/GPR43/GPR41 pathway. Anadditional pathway inducing GLP-1 by microbiota is medi-
ated by intestinal Escherichia coli–derived protein casein-
olytic protease B. Caseinolytic protease B serves as an
antigen mimetic of the a-melanocyte–stimulating hor-
mone59 and is capable of stimulating melanocortin receptor
4 on enteroendocrine L cells to produce GLP-1.60 However,
a recent study showed that GF mice (which lack colonic
SCFAs) show signiﬁcantly higher levels of GLP-1 in the
plasma, while colonization of GF mice with microbiota or
treatment with SCFAs reduced GLP-1 expression in the co-
lon.61 Interestingly, blocking the GLP-1 signaling with
exendin 9-39 (Ex-9) (GLP-1 antagonist) completely rescued
the slow intestinal transit observed in GF mice, and
antibiotic-dependent reduction of intestinal transit was
rescued by deletion of GLP-1, indicating that GLP-1 signaling
is required to slow intestinal transit in GF conditions.
Perhaps slower intestinal transit provides extra time for
nutrient absorption during insufﬁcient colonic energy
availability (lack of SCFAs) under GF conditions. Further
studies will be necessary to determine how SCFAs regulate
the levels of GLP-1 and how GLP-1 controls the activity of
intestinal neural circuits.
An alternative mechanism by which SCFAs could affect
host gene expression is the inhibition of histone deacetylase
activity.62,63 Histone deacetylase inhibition enhances his-
tone acetylation of gene regulatory elements and increases
gene transcription.64 The epigenetic regulation of the
immune system by gut microbial butyrate has been shown
in colonic T cells39,65 and macrophages.66 Although little is
known about the epigenetic modiﬁcations of ENS by SCFAs,
butyrate treatment enhances acetylation of the H3K9 in
primary cultured enteric neurons and the EGC cell line
JUG-2.51,53 It would be interesting to determine the extent to
which microbiota-derived SCFAs modulate the epigenetic
status of genes and its role in enteric neurogenesis and
gliogenesis.Bile Acid Metabolism and Dietary Factors
Gut microbes also participate in the conversion of
primary bile acids synthesized de novo in the liver into
secondary bile acids.17 Secondary bile acids can activate the
G-protein–coupled bile acid receptor 1, which is known as
TGR5. TGR5 is highly expressed in enteric neurons and
enteroendocrine L cells67 and TGR5-deﬁcient mice showed
delayed colonic transit and reduced defecation frequency
relative to wild-type mice.68 In addition, stimulation with
TGR5 agonists induced colonic peristalsis in wild-type but
not TGR5-deﬁcient mice, suggesting the important role of
TGR-5 signaling on intestinal propulsive activity. TGR5-
dependent enhancement of peristalsis could be mediated
partly by production of 5-HT, because stimulation of
isolated distal colon with bile acids increased 5-HT pro-
duction.68 Although a better mechanistic understanding is
required, targeting of TGR5 emerges as a potential thera-
peutic strategy to alleviate symptoms of constipation and
diarrhea.
Diet ingredients also can inﬂuence gut motility and ENS
function in combination with microbiota. A recent study
Figure 1.Microbiota and diet control the activity of multiple cell types in the gut wall, including the ENS. For example, the
bacterial metabolites SCFAs activate G-protein coupled receptors (eg, GPR41 and GPR43) on enteroendocrine cells of the
intestinal epithelium resulting in enhanced production of GLP-1 and 5-HT and changes in gut motility. Gut microbiota also
contribute to the conversion of primary bile acids into secondary bile acids, which activate TGR5 expressed by enter-
oendocrine cells and enteric neurons. TLR signalling (eg, TLR2 and TLR4) maintains subsets of enteric neurons and inﬂuences
gut motility. In addition, microbiota is essential for the maintenance of mucosal glial cells, which express the neurotrophic
factor GDNF and GFAP. 5-HT, Serotonin; a-MSH, a-melanocyte-stimulating hormone; GDNF, glial cell-derived neurotrophic
factor; GFAP, glial ﬁbrillary acidic protein; GLP-1, glucagon-like peptide-1; SERT, serotonin-selective reuptake transporter;
Tph1, tryptophan hydroxylase 1.
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associated with intestinal transit time phenotype.69 Con-
sumption of a Bangladeshi diet containing turmeric, a spice
that increases luminal bile acids, signiﬁcantly slowed
motility in mice that had been colonized with microbiota
isolated from a Bangladeshi donor, compared with a
turmeric-free Bangladeshi diet, suggesting that a single food
ingredient can inﬂuence gut motility. Because deconjugation
of bile acids is mediated by activity of bacterial bile salt
hydrolases (BSHs), these investigators generated gnotobi-
otic mice composed of either BSH-positive or BSH-negative
bacterial consortia cultured from the microbiota of a
Bangladeshi donor. Intestinal transit time signiﬁcantly
decreased in mice colonized with the BSH-positivemicrobiota than BSH-negative microbiota only when they
were fed a turmeric-containing diet, indicating that the
motility phenotypes are dependent on the abilities of
microbiota to deconjugate the bile acids produced by
turmeric consumption. Interestingly, this phenotype was
not observed in mice heterozygous for a Ret null mutation,
suggesting that the effects of turmeric on motility pheno-
types depend on both genetic background and bacterial bile
acid metabolism.69 Taken together, gut motility is inﬂuenced
in a coordinated manner by the interaction between luminal
environmental factors (eg, diet, SCFAs, bile acids, TLR li-
gands), microbial factors (composition and metabolism ac-
tivity), and host factors (nutritional condition and functional
ENS) (Figure 1).
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the Gut Immune System and ENS
The GI tract harbors the highest concentration of im-
mune cells in the body. In particular, macrophages, which
have key roles in innate immune responses and tissue
homeostasis, are present in intestinal muscularis (called
muscularis macrophages [MMs]) and are in close contact
with ENS cells.70 MMs have a unique surface marker proﬁle
(CX3CR1hiMHCIIhiCD11cloCD103-CD11bþ) and their devel-
opment is dependent on colony stimulatory factor (CSF)1
receptor, a receptor for macrophage CSF that regulates
mononuclear phagocyte development.71 Interestingly,
treatment of adult mice with the anti-CSF1R antibody
induced depletion of MMs and resulted in gut dysmotility,
manifested as colonic hyperactivity and increased colonic
transit time. Bone marrow chimeric mice with Csf1-
receptor–deﬁcient hematopoietic progenitors also showed
increased colonic transit time, indicating the importance of
MMs on the physiological control of GI motility. MM-
dependent control of gut motility is mediated by bone
morphogenetic protein (BMP)2, which is expressed by MMs
and activates enteric neurons.72,73 Administration of the
BMP signaling inhibitor dorsomorphin reproduced the
phenotype of MM-depleted mice whereas exogenous BMP2
rescued the dysmotility of these animals. Remarkably,
enteric neurons selectively express BMP receptor type II, a
component of the BMP receptor, and can produce CSF1 that
is required for MM development. CSF1-deﬁcient mice
harbored an increased number of enteric neurons and
showed a less-organized ENS architecture. These results
suggest that neuronal CSF1 contributes to the homeostasis
of MMs, which then are required for normal ENS activity.Interestingly, production of CSF1 and BMP2 is dependent on
gut microﬂora because antibiotic treatment decreased the
production of both signaling mediators.71
More recently, Gabanyi et al74 performed RNA
sequencing–based transcriptome analysis of MMs and
lamina propria macrophages, and showed that MMs pref-
erentially express tissue-protective and wound-healing
genes resembling alternatively activated (M2-type) mac-
rophages, while lamina propria macrophages express
proinﬂammatory genes. Interestingly, MMs express Adrb2
(encoding b2 adrenergic receptors), which is essential for
norepinephrine signaling, and reside in close proximity to
enteric neurons labeled with the calcium indicator
GCaMP3, suggesting that MMs interact with active neurons
in gut muscularis. Of note, intestinal infection with a
mutant strain of Salmonella typhimurium activated tyrosine
hydroxylase–expressing extrinsic neurons in the sympa-
thetic ganglia innervating the gut, leading to production of
norepinephrine in the muscular layer, which was accom-
panied by a signiﬁcant increase in intestinal transit time.
The noradrenaline signaling on MMs through b2 adrenergic
receptors also contributed to their polarization into
M2-type–related phenotype. These studies indicate that
microbiota-driven interactions between innate immune
cells and the ENS control gut motility and enhance the
tissue-protective phenotype in MMs in response to intes-
tinal infection, even in sites distal from an initial pathogen
entry.74
In conclusion, these recent studies provide further
support for the concept that specialized interactions
between the ENS and the gut immune system are essential
for GI tract homeostasis (Figure 2). Given the capacity of the
nervous system to respond rapidly to diverse stimuli byFigure 2. BMP2 from
muscularis macrophages
(MMs) regulates the activ-
ity of enteric neurons (by
activating BMPRII) while
CSF1 from enteric neurons
is essential for the devel-
opment of MMs (which
express CSF1R). Produc-
tion of CSF1 and BMP2 is
dependent on gut micro-
biota. Activation of MMs
by norepinephrine (via b2
adrenergic receptors) con-
tributes to their polarization
into M2-type phenotype,
which is associated with
tissue homeostasis and
wound healing. BMP2,
bone morphogenetic pro-
tein 2; b2AR: b2 adrenergic
receptors, CSF1, colony
stimulating factor 1; NE,
norepinephrine.
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include among their targets immune cell functions,75 it is
conceivable that enteric neural reﬂexes are an integral part
of early response mechanisms that operate continuously to
restore the balance between innocuous and pathogenic
micro-organisms and thus maintain the symbiotic
host–microbe relationships.Parkinson’s Disease: A Disease of the
Microbiota–Gut–Brain Axis?
The critical role of the ENS in controlling GI tract phys-
iology is highlighted by the high morbidity of congenital
enteric neuron deﬁcits, such as Hirschsprung’s disease.76
Acquired dysmotility syndromes, such as irritable bowel
syndrome (IBS), also are attributed to ENS deﬁcits, although
additional local factors, including luminal microbiota,
mucosal immune cells, epithelial barrier functions, and se-
rotonin metabolism have been implicated in the pathogen-
esis of this condition.77 IBS also is associated with deﬁcits in
the bidirectional gut–brain communication,78 and studies on
this condition are likely to provide insight into the role on
the MGB axis in health and disease. A detailed presentation
of the relationship between IBS and the MGB axis is beyond
the scope of this review and the reader is directed to
excellent recent literature.77,79 Here, we highlight an
emerging hypothesis implicating ENS deﬁcits in the patho-
genesis of neurodegenerative diseases, including
Parkinson’s disease (PD).80 PD is characterized by selective
degeneration of dopaminergic neurons in the midbrain
substantia nigra, and the abnormal deposition of
a-synuclein (Lewy bodies) in the surviving dopaminergic
neurons, resulting in characteristic motor symptoms.81
However, a high percentage of PD patients also are char-
acterized by abnormal GI motility and constipation.82
Interestingly, PD-associated a-synuclein accumulations
also are found in enteric neurons, which precede the
development of motor symptoms by several years,83 sug-
gesting that the ENS is an initial site of a-synuclein aggre-
gations, which subsequently spread to the brain through
vagus nerve ﬁbers. In support of this notion, the risk of PD is
lower in vagotomized individuals in comparison with the
healthy population.84 Furthermore, a recent study has
shown that a-synuclein injected into the gut wall can
translocate into the dorsal motor nucleus of the vagus nerve
via vagus nerve ﬁbers in a time-dependent manner.85
Nevertheless, it remains unclear whether in PD patients
intestinal PD pathology spreads to the brain and initiates
motor symptoms, and how luminal factors (eg, microbiota
and diet) could inﬂuence the potential gut–brain trans-
location, severity of intestinal symptoms, and loss of
midbrain dopaminergic neurons. Interestingly, PD patients
show dysbiosis, which is correlated with the clinical
phenotype,86 although it has not been determined whether
the observed changes of microbiota contribute to the
pathogenesis of the disease or instead are the consequence
of PD-associated nonmotor symptoms. The other alterations
found in the gut of PD patients was an abnormal increase ofproinﬂammatory cytokine genes and the glial cell markers
GFAP, SOX10, and S100b,87 suggesting an association of
intestinal inﬂammation and glial dysregulation with PD
development. In addition, colonic biopsy specimens from PD
patients showed the presence of enteric glial reactivity
characterized by the up-regulation of GFAP expression but a
reduction in phosphorylation,88 although the pathophysio-
logical signiﬁcance of these abnormalities remains
unknown. Given that PD patients are diagnosed only after
the onset of motor symptoms and are not treated until
signiﬁcant loss of dopaminergic neurons already has
occurred, intestinal PD pathology could be an early and
potentially useful biomarker for this condition.
Conclusions and Future Perspectives
Accumulating evidence suggests that the development
and function of ENS is controlled by luminal microbial factors
and the host immune system. In addition to the importance
of ENS on GI homeostasis, ENS also serves as a relay station
along the MGB axis that conveys information from the
luminal microenvironment to the CNS. The mechanisms
underlying MGB axis communication involve the immune
and endocrine system, neural pathways via the vagus nerve,
and the microbiota-dependent modulation of CNS.8,89–95 For
instance, SCFAs produced by microbiota ensure the integrity
of the blood-brain barrier by up-regulating tight junction
proteins,42 and regulate the maturation and activation of
microglial cells.41 On the other hand, the mechanism directly
controlling the neural pathway connecting the CNS and ENS
by microbial factors remains elusive. Considering that defects
in ENS cause the development of CNS diseases, under-
standing the molecular mechanism of microbiota–ENS in-
teractions could help us generate novel therapeutic
strategies for multiple types of neurodegenerative diseases.References
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